287 related articles for article (PubMed ID: 27990624)
1. Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
Angara K; Rashid MH; Shankar A; Ara R; Iskander A; Borin TF; Jain M; Achyut BR; Arbab AS
Histol Histopathol; 2017 Sep; 32(9):917-928. PubMed ID: 27990624
[TBL] [Abstract][Full Text] [Related]
2. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
3. Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma.
Angara K; Borin TF; Arbab AS
Transl Oncol; 2017 Aug; 10(4):650-660. PubMed ID: 28668763
[TBL] [Abstract][Full Text] [Related]
4. Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.
Shankar A; Borin TF; Iskander A; Varma NR; Achyut BR; Jain M; Mikkelsen T; Guo AM; Chwang WB; Ewing JR; Bagher-Ebadian H; Arbab AS
Onco Targets Ther; 2016; 9():1205-19. PubMed ID: 27022280
[TBL] [Abstract][Full Text] [Related]
5. Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study.
Chen Y; Jing Z; Luo C; Zhuang M; Xia J; Chen Z; Wang Y
Med Oncol; 2012 Mar; 29(1):324-31. PubMed ID: 21161444
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
Rong X; Huang B; Qiu S; Li X; He L; Peng Y
Oncotarget; 2016 Dec; 7(51):83976-83986. PubMed ID: 27824617
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.
Achyut BR; Shankar A; Iskander AS; Ara R; Angara K; Zeng P; Knight RA; Scicli AG; Arbab AS
Cancer Lett; 2015 Dec; 369(2):416-26. PubMed ID: 26404753
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer.
Li S; Zhang Q; Zhou L; Guan Y; Chen S; Zhang Y; Han X
Biomed Pharmacother; 2017 Dec; 96():982-992. PubMed ID: 29208325
[TBL] [Abstract][Full Text] [Related]
11. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.
Shao R; Taylor SL; Oh DS; Schwartz LM
Oncotarget; 2015 Dec; 6(38):40507-18. PubMed ID: 26439689
[TBL] [Abstract][Full Text] [Related]
12. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
13. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.
Mahase S; Rattenni RN; Wesseling P; Leenders W; Baldotto C; Jain R; Zagzag D
Am J Pathol; 2017 May; 187(5):940-953. PubMed ID: 28284719
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
[TBL] [Abstract][Full Text] [Related]
17. HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice.
Borin TF; Zuccari DA; Jardim-Perassi BV; Ferreira LC; Iskander AS; Varma NR; Shankar A; Guo AM; Scicli G; Arbab AS
PLoS One; 2014; 9(12):e116247. PubMed ID: 25549350
[TBL] [Abstract][Full Text] [Related]
18. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
19. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in glioblastoma multiforme: navigating the maze.
Linkous AG; Yazlovitskaya EM
Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
